<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001381</url>
  </required_header>
  <id_info>
    <org_study_id>940098</org_study_id>
    <secondary_id>94-C-0098</secondary_id>
    <nct_id>NCT00001381</nct_id>
  </id_info>
  <brief_title>A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder</brief_title>
  <official_title>A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Patients with superficial transitional cell carcinoma of the bladder will be treated with&#xD;
      intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered&#xD;
      in this fashion will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with superficial transitional cell carcinoma of the bladder will be treated with&#xD;
      intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered&#xD;
      in this fashion will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1994</start_date>
  <completion_date>December 2000</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>18</enrollment>
  <condition>Bladder Neoplasms</condition>
  <condition>Carcinoma, Transitional Cell</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>suramin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Histologically confirmed superficial transitional cell carcinoma of the bladder&#xD;
        pathologically staged as Tis, Ta, or T1. Visible tumors at time of treatment not required.&#xD;
        No metastatic disease or muscle invasion.&#xD;
&#xD;
        Clinically useful pretreatment bladder function required.&#xD;
&#xD;
        No significant prostatic obstructive symptoms associated with impaired or incomplete&#xD;
        bladder emptying.&#xD;
&#xD;
        No active urinary tract infection.&#xD;
&#xD;
        PRIOR/CONCURRENT THERAPY:&#xD;
&#xD;
        At least 1 course of prior standard intravesical therapy required.&#xD;
&#xD;
        At least 4 weeks since intravesical treatment, with resolution of any local or systemic&#xD;
        toxicity.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age: 18 and over.&#xD;
&#xD;
        Performance status: ECOG 0 or 1.&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
        WBC at least 3,300;&#xD;
&#xD;
        Hemoglobin at least 10 g/dL.&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
        Bilirubin no greater than 1.5 mg/dL;&#xD;
&#xD;
        AST and ALT no greater than 2 times normal.&#xD;
&#xD;
        Renal: Creatinine no greater than 1.5 mg/dL.&#xD;
&#xD;
        OTHER:&#xD;
&#xD;
        Medically able to undergo cystoscopy.&#xD;
&#xD;
        No pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gansler T, Vaghmar N, Olson JJ, Graham SD. Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures. J Urol. 1992 Sep;148(3):910-4. doi: 10.1016/s0022-5347(17)36776-9.</citation>
    <PMID>1512858</PMID>
  </reference>
  <reference>
    <citation>Walther MM, Figg WD, Linehan WM. Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. World J Urol. 1996;14 Suppl 1:S8-11. doi: 10.1007/BF00182057.</citation>
    <PMID>8738403</PMID>
  </reference>
  <reference>
    <citation>Walther MM, Trahan EE, Cooper M, Venzon D, Linehan WM. Suramin inhibits proliferation and DNA synthesis in transitional carcinoma cell lines. J Urol. 1994 Nov;152(5 Pt 1):1599-602. doi: 10.1016/s0022-5347(17)32486-2.</citation>
    <PMID>7933214</PMID>
  </reference>
  <verification_date>January 2000</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Adult</keyword>
  <keyword>Intravesical Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suramin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

